𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B

✍ Scribed by T. Vassiliadis; N. Nikolaidis; O. Giouleme; K. Tziomalos; N. Grammatikos; K. Patsiaoura; P. Zezos; D. Gkisakis; K. Theodoropoulos; P. Katsinelos; E. Orfanou-Koumerkeridou; N. Eugenidis

Book ID
108604001
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
90 KB
Volume
21
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutations associated with the therapeuti
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis
✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated

Adding-on versus switching-to adefovir t
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B
✍ Irene Rapti; Evangelini Dimou; Panayota Mitsoula; Stephanos J. Hadziyannis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

We studied the long-term efficacy of adefovir dipivoxil (ADV) treatment in 42 HBeAgnegative patients with chronic hepatitis B (CHB) who had developed genotypical lamivudine (LAM) resistance with virological and clinical breakthroughs under long-term LAM treatment. Patients were allocated in 2 treatm

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60